Coronary stent thrombosis with vorapaxar versus placebo: Results from the TRA 2°P-TIMI 50 trial

Journal of the American College of Cardiology

Volumn 64, Issue 22, 2014, Pages 2309-2317

  Bonaca, Marc P ^a   Scirica, Benjamin M ^a   Braunwald, Eugene ^a   Wiviott, Stephen D ^a   O'Donoghue, Michelle L ^a   Murphy, Sabina A ^a   Morrow, David A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antiplatelet therapy; atherothrombosis; DES; PAR 1; stent; thienopyridine

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; THIENOPYRIDINE DERIVATIVE; VORAPAXAR; LACTONE; PYRIDINE DERIVATIVE; THROMBIN RECEPTOR;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY STENT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RISK ASSESSMENT; RISK REDUCTION; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY THROMBOSIS; DRUG ELUTING STENT; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE;

AGED; ATHEROSCLEROSIS; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRIDINES; RECEPTORS, THROMBIN; STROKE;

EID: 84919443848     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.09.037     Document Type: Article

References (18)

1. L. Mauri, W.H. Hsieh, and J.M. Massaro Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029
2. I. Iakovou, T. Schmidt, and E. Bonizzoni Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
3. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
4. A.A. Bavry, D.J. Kumbhani, and T.J. Helton Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials Am J Med 119 2006 1056 1061
5. S.K. James, U. Stenestrand, J. Lindback SCAAR Study Group Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden N Engl J Med 360 2009 1933 1945
6. S.D. Wiviott, E. Braunwald, C.H. McCabe TRITON-TIMI 38 Investigators Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet 371 2008 1353 1363
7. P.G. Steg, R.A. Harrington, H. Emanuelsson PLATO Study Group Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial Circulation 128 2013 1055 1065
8. D.A. Morrow, B.M. Scirica, K.A. Fox TRA 2°P-TIMI 50 Investigators Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial Am Heart J 158 2009 335 341.e3
9. D.A. Morrow, E. Braunwald, M.P. Bonaca TRA 2°P-TIMI 50 Steering Committee and Investigators Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 2012 1404 1413
10. ZONTIVITY (TM) oral tablets, vorapaxar oral tablets [product information] 2014 Merck & Co., Inc. Whitehouse Station, NJ
11. F. D'Ascenzo, M. Bollati, and F. Clementi Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses Int J Cardiol 167 2013 575 584
12. B.M. Scirica, M.P. Bonaca, E. Braunwald TRA 2°P-TIMI 50 Steering Committee Investigators Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial Lancet 380 2012 1317 1324
13. L. Mauri, D.J. Kereiakes, and S.L. Normand Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions Am Heart J 160 2010 1035 1041 1041.e1
14. S.J. Park, D.W. Park, and Y.H. Kim Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382
15. M. Valgimigli, G. Campo, M. Monti Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
16. M.P. Bonaca, B.M. Scirica, and M.A. Creager Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50 Circulation 127 2013 1522 1529 1529e1-6
17. S.R. Mehta, J.F. Tanguay, J.W. Eikelboom CURRENT-OASIS 7 trial investigators Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
18. C.M. Gibson, P. Tricoci, and C. Abueg Lack of concordance between angiographic core laboratory and CEC in the assessment of stent thrombosis: results from the TRACER angiographic substudy Eur Heart J 34 Suppl 1 2013 240